Verrica Pharmaceuticals (VRCA) Projected to Announce Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $5.7330 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. The business had revenue of $5.02 million for the quarter, compared to the consensus estimate of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Stock Performance

NASDAQ:VRCA opened at $5.22 on Friday. The firm’s fifty day simple moving average is $5.86 and its 200 day simple moving average is $6.14. The company has a current ratio of 2.10, a quick ratio of 1.98 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The firm has a market capitalization of $89.68 million, a price-to-earnings ratio of -5.07 and a beta of 1.47.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Zacks Research upgraded Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in Verrica Pharmaceuticals by 347.5% during the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock valued at $101,000 after purchasing an additional 111,678 shares in the last quarter. Invesco Ltd. lifted its holdings in Verrica Pharmaceuticals by 64.8% in the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after buying an additional 29,256 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Verrica Pharmaceuticals by 306.7% in the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after buying an additional 44,275 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Verrica Pharmaceuticals by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock valued at $61,000 after buying an additional 26,308 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $66,000. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.